KPV — Peptide Reference

01 — Identity

Name & Classification

KPV is a tripeptide composed of three amino acids: Lysine–Proline–Valine. It represents the C-terminal fragment (positions 11–13) of alpha-melanocyte stimulating hormone (α-MSH), which is itself a potent endogenous anti-inflammatory neuropeptide.

KPV is classified as a melanocortin-derived anti-inflammatory peptide. Unlike its parent molecule α-MSH, KPV lacks hormonal activity but retains — and in some studies exceeds — the anti-inflammatory and antimicrobial potency of the full sequence. It acts primarily on gut epithelium, immune cells, and skin via NF-κB pathway inhibition.

Also known as: α-MSH(11-13) | H-Lys-Pro-Val-OH

02 — Origin

When It Was Developed

1980s–90s

Research into α-MSH's anti-inflammatory properties identified that its potency resided primarily in specific sequence fragments. KPV (the C-terminal tripeptide) was isolated and found to replicate key anti-inflammatory effects.

1990s–2000s

Studies by Dr. Anna Catania and others demonstrated KPV's ability to suppress fever, reduce local and systemic inflammation, and inhibit NF-κB signaling without the pigmentation effects of full α-MSH.

2000s–2010s

Growing body of research on gut health applications — KPV shown to reduce intestinal inflammation in IBD models, improve mucosal barrier integrity, and suppress pro-inflammatory cytokine production in colonic tissue.

2015–Present

Increasing use in functional medicine for IBD, leaky gut, skin conditions, and systemic inflammation. Both injectable and oral/topical routes studied. No FDA approval; research peptide status.

03 — Research History

Research Background

KPV was identified through systematic research on which portion of α-MSH was responsible for its powerful anti-inflammatory effects. The tripeptide was found to be the minimal active sequence — capable of inhibiting NF-κB, reducing pro-inflammatory cytokines (TNF-α, IL-6, IL-1β), and suppressing fever in animal models at doses comparable to full-length α-MSH.

Particularly compelling is its role in gut health. Research showed KPV can be taken orally and survives intestinal transit well enough to act locally on colonic mucosa — a major advantage over injectable peptides for gut conditions. Studies in colitis models showed KPV reduced inflammation scores, preserved crypt architecture, and improved barrier function by upregulating tight junction proteins.

KPV also shows direct antimicrobial activity against several pathogens including Candida albicans and Staphylococcus aureus, suggesting a dual role as both anti-inflammatory and antimicrobial agent in mucosal tissues.

04 — Key Benefits

Proposed Benefits

Potent NF-κB inhibition — master inflammation switch

Reduces TNF-α, IL-6, IL-1β in gut and systemic tissue

Heals intestinal mucosal barrier — tight junction upregulation

Effective in IBD/colitis models (Crohn's, UC)

Oral route viable — survives gut transit to act locally

Antimicrobial activity against Candida and Staph aureus

Skin anti-inflammatory — effective topically for dermatitis

No hormonal activity — no pigmentation or endocrine effects

05 — Reconstitution

10 mg Vial + 300 Units BAC Water

33.3 mcg

per unit drawn on insulin syringe

10,000

mcg total

0.3 mL

total volume

4–6 wk

shelf life (fridge)

KPV is also available in oral capsule form (typically 500 mcg–2 mg per capsule) for targeted gut action. Injectable form reconstituted with BAC water as above. For gut-focused protocols, oral is preferred; for systemic or skin applications, subcutaneous injection or topical is used. Store refrigerated at 2–8°C.

06 — Dosage

Dosage Reference

Dose	Units / Format	Context
100–250 mcg SC	3–7.5 u	LOW / INTRO
500 mcg SC	15 u	COMMON (injectable)
500 mcg–2 mg oral	1–4 capsules	GUT PROTOCOL
1–2 mg SC	30–60 u	STANDARD

KPV is well-tolerated with a very wide safety margin given its endogenous origin. For gut/IBD protocols, oral dosing 500 mcg–2 mg/day is typical. For systemic inflammation, subcutaneous 500 mcg–1 mg/day is common. Oral and injectable can be combined for dual systemic + local gut effect.

07 — Monitoring

Biomarkers, Lab Tests & Ranges

KPV targets intestinal inflammation, systemic inflammatory cytokines, and gut barrier integrity. Monitor these markers before, at 6 weeks, and at cycle end.

▸ Gut Barrier & Intestinal Health

Biomarker	Lab Test	Clinical Range	Optimal Range
Zonulin Intestinal permeability marker	Serum or Stool Zonulin	CLINICAL<107 ng/mL (serum)	OPTIMAL<40 ng/mL
LPS (Lipopolysaccharide) Bacterial translocation marker	Serum LPS / LPS-binding protein	CLINICALLBP <7.5 µg/mL	OPTIMALLBP <5.0 µg/mL
Calprotectin Gut inflammation marker	Stool Calprotectin	CLINICAL<50 µg/g	OPTIMAL<25 µg/g
Secretory IgA (sIgA)	Stool sIgA	CLINICAL510–2040 µg/g	OPTIMAL700–1500 µg/g

▸ Systemic Inflammation

Biomarker	Lab Test	Clinical Range	Optimal Range
hsCRP	High-sensitivity CRP	CLINICAL<3.0 mg/L	OPTIMAL<0.5 mg/L
IL-6	Serum Interleukin-6	CLINICAL<7.0 pg/mL	OPTIMAL<1.5 pg/mL
TNF-α	Serum TNF-alpha	CLINICAL<8.1 pg/mL	OPTIMAL<2.0 pg/mL
ESR	Erythrocyte Sedimentation Rate	CLINICAL0–22 (M) / 0–29 (F) mm/hr	OPTIMAL<10 mm/hr

▸ Safety

Biomarker	Lab Test	Clinical Range	Optimal Range
AST / ALT	CMP	CLINICALAST 10–40 / ALT 7–56 U/L	OPTIMALAST <26 / ALT <26 U/L
CBC	Complete Blood Count	CLINICALStandard ranges	OPTIMALMid-range; WBC 4.5–6.0

⚠ KPV is not FDA-approved. It is derived from an endogenous sequence (α-MSH) and has a strong safety profile in research. Stool testing (calprotectin, zonulin, sIgA) is particularly valuable for tracking gut-focused protocols. Consult a qualified practitioner.

08 — Cycle Protocol

Cycle Length, Frequency & Timing

▸ How Long to Cycle

RESEARCH PROTOCOLS

8–12 Weeks

Animal IBD and colitis studies used 4–12 week treatment courses. Functional improvements in gut histology visible from week 4.

PRACTITIONER CONSENSUS

12–16 Weeks

Gut healing typically requires sustained support. Most practitioners run 12–16 week cycles for IBD/leaky gut, with off-period biomarker reassessment before re-cycling.

KPV has one of the most favorable safety profiles of any research peptide given its endogenous origin. Longer cycles are considered acceptable. For chronic gut conditions, some practitioners use intermittent longer protocols with periodic breaks every 16–20 weeks.

▸ Frequency & Timing

Variable	Recommendation	Why
Frequency (injectable)	Daily (7×/week)	Daily dosing maintains consistent NF-κB suppression. KPV's short half-life means consistent daily administration is needed for systemic effect.
Frequency (oral)	1–2× daily with food	Oral dosing with meals delivers KPV to intestinal epithelium during digestion — maximizing local gut contact time. Split AM/PM dosing for twice-daily regimens.
Fasted vs Fed (injectable)	~ Either acceptable	Unlike metabolic peptides, KPV does not require a fasted state. Its anti-inflammatory mechanism is not insulin-sensitive. AM fasted is conventional; no strong data for preference.
Fasted vs Fed (oral)	✓ With food	Taking oral KPV with food extends gut contact time and maximizes local anti-inflammatory effect on intestinal mucosa. The transit time through the gut is the delivery window.
Timing	AM preferred	Morning dosing aligns with peak inflammatory cytokine production (which is typically highest in the early morning). May be most effective when administered before the daily inflammatory peak.

PROTOCOL SUMMARY

12–16 wk

CYCLE LENGTH

Daily

FREQUENCY

AM

TIMING

Oral or SC

ROUTE

4–8 wk

BREAK